MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
attributable to common...
-$45,876K
(-0.93%↓ Y/Y)
Interest income
$3,104K
(-4.76%↓ Y/Y)
Other income
(expense), net
$5K
(112.82%↑ Y/Y)
Net loss
-$45,851K
(-0.92%↓ Y/Y)
Preferred stock dividend
payable on series a...
$25K
(4.17%↑ Y/Y)
Total other income
(expense), net
$3,109K
(-3.45%↓ Y/Y)
Loss from operations
-$48,960K
(-0.64%↓ Y/Y)
Royalty revenues
$593K
(-13.18%↓ Y/Y)
Total operating
expenses
$49,553K
(0.44%↑ Y/Y)
Research and development
$35,329K
(-4.13%↓ Y/Y)
Selling, general and
administrative
$14,224K
(13.96%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Cardiff Oncology, Inc. (CRDF)
Cardiff Oncology, Inc. (CRDF)